OptimizeRx Partners with Komodo Health to Expand Life Sciences Support at Point-of-Care
07 Dezember 2020 - 1:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies, physicians and
patients, has partnered with Komodo Health, a data-driven
healthcare software company with access to the broadest array of
real-world data across patients, practitioners, and health
systems.
The partnership integrates Komodo’s comprehensive Healthcare Map
with OptimizeRx’s digital health and communication platform to
power OptimizeRx’s novel real-world evidence (RWE) solution. The
solution leverages automated intelligence through machine-learning
and APIs to seamlessly deliver point-of-care messaging.Komodo’s
real-world visibility into millions of patient journeys and
healthcare provider actions across all therapeutic areas will
enable OptimizeRx to deliver richer insights to physicians through
its digital health network. This visibility expands OptimizeRx’s
total addressable audience, giving its life science clients
unparalleled ability to reach and support clinicians at precise
moments at the point-of-care. The API-driven integration
supplements OptimizeRx’s recent platform enhancement involving the
application of advanced analytics using machine learning methods
applied to real-world-data (RWD). “Accurate, timely, real-world
patient insights through digital platforms have become critically
important given that COVID-19 has fundamentally changed how
providers deliver care,” said Jason Prestinario, head of healthcare
solutions at Komodo Health. “Pairing our comprehensive patient
insights with OptimizeRx’s powerful provider communications
platform will enable a transformative patient experience at the
point-of-care.”
As the COVID-19 pandemic has demonstrated, prescribed therapies
can change or evolve rapidly. Yet there are few channels currently
available that can efficiently reach healthcare providers with
timely insights on new therapies and other important care
considerations. Scientific advances can also emerge rapidly, but it
often takes 10-15 years for an important medical breakthrough to
become the standard of care. These gaps can lead to sub-optimal
care and outcomes for patients.
“As our digital health footprint expands with more manufacturers
coming onto our platform, we continue working relentlessly to
steward health data in ways that can efficiently yield better
outcomes as well as provide savings for patients,” said Steve
Silvestro, chief commercial officer at OptimizeRx. “Our partnership
with Komodo Health enables us to augment the physician workflow
with actionable insights. By providing additional real-time
critical information for clinicians dealing with complex healthcare
scenarios, we can improve the patient and physician experience and
ultimately treatment outcomes.”
About Komodo HealthKomodo Health believes that
smarter, more innovative use of data and analytics is essential for
reducing disease burden. We apply advanced data science techniques
to our first-of-its-kind Healthcare Map™, which tracks the unique
patient journeys of over 320 million patients. Using our
cloud-based platform and application suite, we empower a multitude
of healthcare stakeholders — life science companies, healthcare
payers and providers, patient advocacy groups, and others — to
create a more cost-effective, value-driven healthcare system. For
more information, visit komodohealth.com.
About OptimizeRxOptimizeRx is a digital health
company that provides communications solutions for life science
companies, physicians and patients. Connecting over half of
healthcare providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health platform helps
patients afford and stay on medications. The platform unlocks new
patient and physician touchpoints for life science companies along
the patient journey, from point-of-care, to retail pharmacy,
through mobile patient engagement.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx Contact Doug Baker, CFOTel
(248) 651-6568 (x807)dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 Email Contact
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Okt 2023 bis Okt 2024